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Abstract
Background: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression
would decrease with longer duration of viral suppression.
Methodology: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in San
Francisco. Adherence to antiretroviral therapy was measured through pill counts obtained at unannounced visits by
research staff to each participant’s usual place of residence. Marginal structural models and targeted maximum likelihood
estimation methodologies were used to determine the effect of adherence to antiretroviral therapy on the probability of
virologic failure during early and late viral suppression.
Principal Findings: A total of 221 subjects were studied (median age 44.1 years; median CD4+ T cell nadir 206 cells/mm3).
Most subjects were taking the following types of antiretroviral regimens: non-nucleoside reverse transcriptase inhibitor
based (37%), ritonavir boosted protease inhibitor based (28%), or unboosted protease inhibitor based (25%). Comparing the
probability of failure just after achieving suppression vs. after 12 consecutive months of suppression, there was a statistically
significant decrease in the probability of virologic failure for each range of adherence proportions we considered, as long as
adherence was greater than 50%. The estimated risk difference, comparing the probability of virologic failure after 1 month
vs. after 12 months of continuous viral suppression was 0.47 (95% CI 0.23–0.63) at 50–74% adherence, 0.29 (CI 0.03–0.50) at
75–89% adherence, and 0.36 (CI 0.23–0.48) at 90–100% adherence.
Conclusions: The risk of virologic failure for adherence greater than 50% declines with longer duration of continuous
suppression. While high adherence is required to maximize the probability of durable viral suppression, the range of
adherence capable of sustaining viral suppression is wider after prolonged periods of viral suppression.
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Introduction
Medication adherence is the most important predictor of viral
suppression among HIV infected patients receiving combination
antiretroviral therapy [1–3]. The adherence threshold required to
achieve durable viral suppression has declined with more potent
regimens, such that the majority of patients in clinical practice are now
able to maintain undetectable viral loads at adherence proportions as
low as 70% [4–7]. Although the relationship between adherence and
the short-term virologic response to therapy has been well described,
the impact of successful treatment duration on the relationship between
adherence and viral suppression remains unexamined.
Several independent observations suggest that the degree of
drug pressure necessary to initially achieve viral suppression may
be higher than that needed to maintain viral suppression. During
effective antiretroviral therapy, plasma HIV RNA levels decline in
a characteristic multi-phasic manner. The rapid first phase decay
likely reflects the death of actively turning over, short-lived CD4+
T cells, while each subsequent phase likely reflects the death of
longer lived cellular reservoirs [8]. After a period of 2 to 5 years,
most patients reach a new steady-state in which the long-lived
reservoir (presumed to be resting CD4+ T cells) continues to
produce a steady-state level of viremia [9,10]. Since the size of the
reservoir containing replication competent virus declines over time
[11], it is reasonable to postulate that the amount of virus that is
able to initiate new rounds of replication also declines, as does the
reservoir of pre-existing drug-resistant variants. Long-term
HAART (highly active antiretroviral therapy) is also associated
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with decline in the number of activated and/or proliferating
CD4+ T cells [12,13]. Since these cells are the primary target cells
for virus production, it is likely that the ability of virus to escape
drug pressure declines proportionally with the decline in these cells
[14]. These observations have been used as a rationale for a series
of induction-maintenance clinical trials, in which patients are
initially treated with more potent regimens and then later switched
to a better tolerated, less potent regimen. Although many of the
earlier trials failed [15,16], more recent studies using longer
induction periods and/or better maintenance regimens have
provided some support for this approach [17,18].
Based on these theoretical considerations, we hypothesized that
the impact of adherence on the probability of virologic failure
would differ depending on how long a subject had maintained
virologic suppression. To test this hypothesis, we examined the
effect of adherence on viral load after different durations of viral
suppression. Subjects for this study were enrolled in a systematic
community-based sample of HIV infected urban poor individuals
living in San Francisco (the REACH cohort) [19]. Adherence was
measured using unannounced pill counts at the participant’s usual
place of residence, as previously described [20]. This method has
a close association with concurrent viral load [2], electronic pill
cap adherence assessment [20], development of resistance
[21,22], and progression to AIDS [23]. We used marginal
structural models [24–26] and targeted maximum likelihood




The University of California San Francisco and Committee on
Human Subjects Research and the Partner’s Human Research
Committee approved all procedures.
Study design and subject recruitment
Participants enrolled in the REACH cohort were invited to
participate in a substudy focused on intensive adherence
monitoring, as previously described [25,28,29]. Briefly, subjects
had unannounced visits by research staff at their usual place of
residence every three to six weeks, over a one year period. Percent
adherence was determined from the number of remaining or
unused antiretroviral pills and number of pills refilled between
visits [2]. Three hundred and fifty seven HIV-positive subjects
were monitored for medication adherence. The earliest monitor-
ing period started in March 1998 and the latest monitoring date
was in October 2007.
Confounding variable assessment
Confounders of the effect of current adherence on virologic
failure included the following: prior adherence, prior duration of
HAART, prior exposure to mono/dual nucleoside therapy, recent
CD4+ T cell count (lagged 2 months), CD4+ T cell nadir (lagged 2
months), demographics (sex, ethnicity, age), years of education,
past and current antiretroviral treatment characteristics, crack
cocaine and alcohol use, calendar time, and homelessness. Current
antiretroviral treatment was classified as one of five potential
regimens: ritonavir boosted protease inhibitor containing regimen,
unboosted protease inhibitor containing regimen, non-nucleoside
reverse transcriptase inhibitor containing regimen (NNRTI),
combined non-nucleoside reverse transcriptase inhibitor-protease
inhibitor containing regimen (PI/NNRTI), and nucleoside reverse
transcriptase inhibitor (NRTI) only containing regimen.
Specimen collection
Blood was drawn monthly for HIV RNA levels (viral loads) and
quarterly for CD4+ T cell levels. HIV-1 viral load was performed
using the HIV-1 Amplicor Monitor Version 1.0 ultra sensitive
assay (Roche Molecular Systems, Alameda, CA).
Statistical analyses
For every month of observation, each REACH cohort
participant was classified as experiencing either virologic suppres-
sion (defined as HIV RNA less than 50 copies/ml) or virologic
failure (defined as HIV RNA at least 50 copies/ml). Each
participant in the REACH cohort who was suppressed for at
least two consecutive months during adherence monitoring
contributed data to the analysis; there were 221 participants
who met this criterion. For each such participant, his/her data was
included starting at the first month of viral suppression during
adherence monitoring and continuing until virologic failure
occurred or the adherence monitoring period ended.
Duration of suppression at any month was defined as the
number of prior consecutive months of viral suppression. In
calculating the duration of viral suppression, we used data on viral
loads prior to the initiation of adherence monitoring.
We used marginal structural models to estimate the effect of
adherence during a given month on the probability of virologic
failure at the end of that month. These effects were estimated within
subpopulations defined by duration of prior viral suppression. For
example, among participants who had maintained viral suppression
for exactly 4 consecutive months, we estimated the effect of
adherence during month 5 on the probability of virologic failure at
the end of month 5. For our primary analysis, adherence was
stratified into the following four categories: 0249%, 50274%,
75289%, or 902100% pills taken. The marginal structural model
was fit using a targeted maximum likelihood estimator (TMLE)
[27], in order to adjust for the potential confounders listed above.
The TMLE, in this application, relies on 1) a multinomial logistic
regression model for predicting medication adherence given
potential confounders and number of consecutive months virally
suppressed and 2) a logistic regression model for the probability of
virologic failure given adherence, confounders, and number of
consecutive months virally suppressed. The TMLE is robust to
model misspecification, in that it gives asymptotically unbiased
estimates whenever at least one of the models (1) or (2) is correct. It
also has several advantages over alternative estimation techniques,
such as inverse probability of treatment weighting [30], g-
computation [31,32], and doubly robust estimators [33–36]; these
advantages have been previously described [27].
Based on the marginal structural model fit using targeted
maximum likelihood estimation, we estimated the probabilities of
virologic failure at each set stratum of adherence, for duration of
continuous suppression ranging from 1 to 12 months. Confidence
intervals for the difference between the probability of failure after
1 month of continuous suppression and the probability of failure
after 12 months of continuous suppression, at each adherence
stratum, were calculated using 10,000 iterations of the nonpara-
metric bootstrap (BCa method) [37].
We tested for effect modification based on the estimated
coefficients of the marginal structural models. More precisely, we
tested whether the effect of the proportion of medication taken on
the probability of virologic failure in the current month, is
impacted by the number of consecutive months one has been
virally suppressed. This test involved first computing the logarithm
of the causal relative risk of virologic failure, comparing high
adherence (90–100%) vs. low adherence (0–49%), conditional on
number of consecutive months virally suppressed. This causal
Risk of Virologic Failure
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relative risk was based on the fit of the marginal structural model
discussed above. Next, we used a linear regression model to test
the null hypothesis that the causal relative risk does not depend on
the number of consecutive months virally suppressed. Standard
errors were computed using the nonparametric bootstrap as
above.
Time-lagged confounder measurements were used to ensure that
confounders occurred before, and thus could not be influenced by,
medication adherence. We imputed missing confounder values by
carrying the most recent observation forward. Because subjects
could contribute data at multiple time points, bootstrap resampling
was based on subject rather than data-point.
Results
Participant characteristics
Of the 357 subjects in the REACH cohort who received
unannounced pill counts, 221 met our criteria for inclusion in the
analysis. The median age at start of adherence monitoring was 44.1
years (IQR 10.5). The median CD4+ T cell count was 390 cells/
mm3 and the median CD4+ T cell nadir was 206 cells/mm3. Fifty-
six of the 221 participants (25%) were receiving an unboosted
protease inhibitor based regimen. The mean observed duration of
continuous viral suppression was 6.7 months. Of the 1201 subject-
months of observation, 95 (8%) were missing adherence measure-
ments and 159 (13%) were missing viral load measurements. See
Tables 1 and 2 for a more extensive list of participant characteristics.
Adherence over time
Unannounced pill count adherence ranged from 0 to 100%,
with a median of 92%. In univariate analyses, higher adherence
was associated with higher past adherence, longer duration of viral
suppression, higher CD4+ nadir, and white/Caucasian ethnicity,
while lower adherence was associated with use of crack,
intravenous drug use, and Black/African American ethnicity.
Comparing observed adherence proportions among subjects who
maintained viral suppression for different durations of time, there
was a gradual decrease in the proportion with 0–49% adherence
Table 1. Participant Characteristics at Start of Adherence Monitoring.
Characteristic
Among Subjects Achieving Viral Suppression
During Adherence Monitoring (n=221) Missing (%)
Non-Caucasian (%) 130 (59%) 3 (1%)
Male (%) 149 (67%) 10 (5%)
Median age (IQR) 44.1 (10.5) 0
Antiretroviral Treatment
PIbased (%) 56 (25%) 0
NNRTI -based (%) 81 (37%) 0
PI-NNRTI-based (%) 15 (7%) 0
NRTI-only (%) 7 (3%) 0
Ritonavir boosted protease inhibitor based 62 (28%) 0
Once daily therapy (%) 81 (37%) 0
Median months on current regimen (IQR) 7 (13) 0
Median number of ARV regimens experienced (IQR) 2 (2) 2 (,1%)
ARV naı¨ve (%) 100 (46%) 2 (,1%)
Mono or dual nucleoside exposure (%) 81 (37%) 2 (,1%)
doi:10.1371/journal.pone.0007196.t001
Table 2. Participant Characteristics During Follow-up.
Characteristic
Among Subjects Achieving Viral
Suppression (n =221) Missing (%)
Intravenous drug use reported in last 30 days at least once during follow-up (%) 34 (15%) 31 (14%)
Crack use (%) 44 (20%) 31 (14%)
Slept on street or in shelter (%) 12 (5%) 36 (16%)
Mean days intoxicated in past month (SD) 3.5 (7.2) 31 (14%)
Median nadir CD4+/ml (IQR) 206 (279) 30 (14%)
Median CD4+/ml (IQR) 390 (338) 5 (2%)
Person-months with pill box organizer use, excluding subject-months with missing data (%) 274 (45%) 0 (0%)
Mean duration of continuous viral suppression in months (SD) 6.7 (4.3) 0 (0%)
Mean viral load at month of failure, in log copies/ml (IQR) 2.7 (1.0) 0 (0%)
Median pill count adherence (IQR) 0.92 (0.25) 95 (8%)
doi:10.1371/journal.pone.0007196.t002
Risk of Virologic Failure
PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7196
(from 11% of subject-months at 1 month of suppression to 5% of
subject-months at 12 months of continuous suppression) and 50–
74% adherence (from 19% of subject-months at 1 month of
suppression to 15% of subject-months at 12 months of continuous
suppression). There was a corresponding gradual increase in the
proportion with 75–89% adherence (from 19% of subject-months
at 1 month of suppression to 25% of subject-months at 12 months
of continuous suppression) and 90–100% adherence (from 50% of
subject-months at 1 month of suppression to 55% of subject-
months at 12 months of continuous suppression). None of these
changes in the proportion of participants at a given adherence
level was statistically significant at the 0.05 level.
Duration of viral suppression and incidence of virologic
failure
Of the 221 participants who achieved viral suppression during
adherence monitoring, 108 (49%) subsequently experienced
virologic failure during adherence monitoring. Based on univariate
regression analyses, participants who had longer duration of
suppression also had higher CD4+ counts, higher CD4+ nadir,
and higher cumulative average adherence proportions. Partici-
pants who had longer duration of suppression were also more
likely to be on an NNRTI or PI/NNRTI regimen than an
unboosted protease inhibitor regimen. Virologic failure (defined as
a plasma HIV RNA greater than 50 copies/ml) was associated
with low recent CD4+ T cell count, low past adherence, shorter
duration of prior suppression, and intravenous drug use.
A logistic regression of the probability of virologic failure on
adherence, confounders, and number of months since initial
suppression was used in the targeted maximum likelihood analysis
(see Table 3). Based on this logistic regression, a lower risk of
virologic failure was associated with longer duration of continuous
suppression, lower past viral load, and being on an NNRTI-based
regimen.
Table 3. Multivariate Regression of Virologic Failure on Adherence, Duration of Continuous Suppression, and Confounders.
Term in Multivariate Linear Regression Model Coefficient 95% CI Lower Limit 95% CI Upper Limit
Indicator of Adherence 0–49% 0.51 21.02 1.76
Indicator of Adherence 50–74% 0.72 20.48 1.76
Indicator of Adherence 75–89% 20.06 21.44 1.1
Months of Continuous Suppression 20.27 20.53 20.11
Indicator of Interaction: Adherence 0–49% x Months of Continuous Suppression 0.24 20.03 0.54
Indicator of Interaction: Adherence 50–74% x Months of Continuous Suppression 0.04 20.24 0.33
Indicator of Interaction: Adherence 75–89% x Months of Continuous Suppression 0.18 20.09 0.46
Once daily therapy 0.29 20.61 1.07
Pillbox Use 0.33 20.59 1.19
CD4 T cell count (2 months prior) (per 100 cells) 20.01 20.01 0
Nadir CD4 T cell count (2 months prior) (per 100 cells) 0 20.01 0
Viral load (2 months prior) (per 100,000 copies) 0.57 0.13 1.06
Calendar month (per 30 days) 20.01 20.03 0
Months on current regimen (per 30 days) 20.01 20.02 0
Age (per year) 20.01 20.05 0.03
Number of days intoxicated (in past month) 20.02 20.07 0.02
Intravenous drug use 0.39 20.6 1.27
Slept on street or in shelter 1.21 20.59 2.49
Crack use 0.2 20.82 1.01
Man 0.17 20.61 0.9
Black/African-American (Ethnicity Response ‘‘Other’’ used as baseline) 0.95 20.04 1.88
Hispanic/Latino 0.71 20.96 2.06
White/Causasian 0.58 20.48 1.46
Mono or dual nucleoside exposure 0.58 20.35 1.35
Unboosted PI-based regimen 0.05 20.93 1
NNRTI-based regimen 20.99 21.68 20.07
PI-NNRTI-based regimen 21.24 22.88 0.37
NRTI only regimen 20.13 24.14 2.21
Number of regimens experienced 20.17 20.35 0.04
Depression (BDI.14) 0.61 20.31 1.29
Years of Education 0.08 20.06 0.23
Adherence lagged 1 month 20.02 21.97 2.27
Cumulative mean adherence lagged 1 month 0.71 22.33 3.5
doi:10.1371/journal.pone.0007196.t003
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Duration of viral suppression modifies the effect of
adherence on virologic failure
We first estimated the causal effect of different adherence
proportions on the probability of virologic failure, conditioned on
duration of continuous viral suppression (Figure 1). We stratified
subject-months by corresponding duration of suppression and then
estimated the probability of virologic failure setting the adherence
proportion to be in the ranges (0–49%, 50–74%, 75–89%, and
90–100%). Because adherence proportion cannot be randomly
assigned as an intervention, we relied on a marginal structural
model and targeted maximum likelihood estimation of the causal
effects of adherence on viral suppression at each time point.
  
  
Figure 1. Estimates and 95% Confidence Intervals for the Risk of Virologic Failure, at Four Ranges of Adherence, Given Duration of
Continuous Viral Suppression.
doi:10.1371/journal.pone.0007196.g001
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At one month of suppression, the estimated probabilities of
virologic failure at all four adherence categories were relatively
high: 0.36 for 0–49% adherence, 0.49 for 50–74% adherence,
0.34 for 75–89% adherence, and 0.37 for 90–100%. The widths of
the confidence intervals for these estimates were large (ranging
from 0.24 to 0.43), and there was a substantial region of mutual
overlap among all four confidence intervals.
The point estimates for the probability of virologic failure
decreased with longer duration of suppression (Figure 1). The
probabilities of virologic failure after 12 months of viral
suppression were 0.24, 0.02, 0.06, and 0.01 for adherence
categories of 0–49%, 50–74%, 75–89%, and 90–100%, respec-
tively. Comparing the probability of failure just after achieving
suppression versus after 12 consecutive months of suppression,
there was a statistically significant decrease in the probability of
virologic failure for adherence set above 50%. The estimated risk
difference, comparing the probability of virologic failure after 1
month vs. after 12 months of continuous viral suppression was
0.47 (95% CI 0.23–0.63) for the 50–74% adherence stratum, 0.29
(95% CI 0.03–0.50) for 75–90% adherence stratum, and 0.36
(95% CI 0.23–0.48) for the 90–100% adherence stratum. The
estimated risk of failure decreased by only 0.13 (95% CI 20.74–
0.39) for the 0–49% adherence stratum, which was not statistically
significant at the 0.05 level.
We carried out a test for effect modification by number of
consecutive months virally suppressed. We considered the causal
relative risk, comparing the effect of different adherence
proportions on the probability of virologic failure. This causal
relative risk was calculated conditioning on the number of months
of viral suppression, using a marginal structural model. The null
hypothesis that this causal relative risk does not depend on the
number of consecutive months virally suppressed was rejected (p-
value 0.001). Thus, the data provide evidence for duration of
suppression being an effect modifier of the adherence-suppression
relationship.
Discussion
Treatment adherence is widely accepted as the primary
determinant of long-term virologic outcomes among antiretrovi-
ral-treated patients. These data suggest that for adherence
proportions greater than 50%, the probability of virologic failure
decreases with longer duration of viral suppression. For example,
we estimated the risk of virologic failure for adherence between
75–89% (which is the most common adherence range in most
chronic diseases) to be 0.31 after 1 month of suppression. In
contrast, we estimated the risk of virologic failure for adherence
between 75–89% to be 0.06 after 12 months of suppression.
Similar trends were observed in those with adherence in the ranges
50 to 74%, and 90 to 100%.
Consistent with our finding that the impact of adherence on
viral suppression is modified by history of successful treatment are
a number recent induction-maintenance studies. For example,
lopinavir-ritonavir monotherapy leads to higher rates of viral
suppression once patients achieve suppression on standard
regimens than when lopinvavir-ritonavir monotherapy is used as
de novo [38,39]. Similarly, the use of a triple nucleoside reverse
transcriptase inhibitor appears to be more effective after viral
suppression is achieved than when the regimen is used as an initial
regimen [17,40].
One important limitation in our analysis is the potential role of
selection bias in explaining the decrease in probability of virologic
failure among those with longer duration of suppression. That is,
those susceptible to virologic failure may have been selected out at
earlier months, leaving a group with lower probability of failure at
later months. Thus, we cannot exclude selection bias as a potential
explanation for these findings.
There are several other limitations that deserve comment.
While we did have extensive and systematic adherence data, we
did not have as extensive virologic suppression data on all
individuals, since some people entered the cohort already on
treatment. These individuals may have had additional periods of
viral suppression that were not included in this analysis. The
estimation method we used relied on having included all
confounders of adherence and virologic failure in our analyses,
and on our marginal structural model and other models used
being correctly specified. While we included many of the known
predictors of adherence and virologic failure, unmeasured
confounders may lead to bias in our estimates. Finally we studied
patients on a wide range of antiretroviral therapy and some
regimens we studied are no longer commonly used. We did not
have the statistical power to limit analyses to just individuals on
NNRTI or ritonavir boosted protease inhibitor based regimens.
While the adherence proportion required to sustain viral
suppression may decline over time, the goal of near perfect
adherence should remain unchanged. While both more potent
therapy and sustained viral suppression may lessen the virologic
consequences of missed doses, improving adherence will increase
the probability of durable and sustained viral suppression [7,41].
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